Drug intelligence / Profile preview

AR169

Development stage: Unknown
Lead developer: Y Biologics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AR169 is a multispecific antibody developed by Y Biologics using its proprietary Multi-Abkine platform. It is designed to simultaneously target two key immune checkpoints: Programmed cell death protein 1 (PD-1) and Lymphocyte-activation gene 3 protein (LAG-3). By blocking these inhibitory pathways, AR169 aims to overcome T-cell exhaustion and synergistically enhance the immune system's ability to identify and destroy cancer cells. The drug is currently in Phase 1 clinical development for the treatment of advanced solid tumors, representing a next-generation approach to immunotherapy beyond single-agent checkpoint inhibition.

Targets

LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on AR169.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR169.

Explore the full profile